IBSchek® - The First Clinically Validated Blood Test for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M)

Now Only $199

An IBSchek order consists of a requisition form, an instruction sheet, a prepaid label, and all necessary shipping supplies. All other supplies needed to perform the draw will be supplied by the draw site of the patient’s choice.

Irritable bowel syndrome (IBS) is one of the most prevalent gastrointestinal conditions in the world. In the United States alone, it is estimated that nearly 45 million patients suffer from IBS while nearly 30 million of those patients are undiagnosed. Some of the most common symptoms associated with IBS are diarrhea, constipation, diarrhea alternating with constipation, abdominal bloating, cramping, pain, and gas.

IBSchek, a blood test designed to help physicians quickly and reliably diagnose diarrhea-predominant or mixed symptom IBS (IBS-D/M), is the first clinically validated blood test to positively diagnose IBS based on the presence of antibodies to a toxin from gastroenteritis called CdtB, as well as vinculin, a protein found in the lining of the gut.

IBSchek is a proprietary blood test for IBS based on the scientific findings of Mark Pimentel, MD, and his team of gastrointestinal experts at Cedars-Sinai Medical Center in Los Angeles. Dr. Pimentel and his team conducted a 2500+ patient clinical trial which showed that anti-vinculin and anti-CdtB are effective biomarkers for the diagnosis of diarrhea-predominant or mixed symptom IBS. The test utilizes a proprietary, ELISA-based blood test. IBSchek requires just 3 mL of blood, which can be drawn in any healthcare provider’s office or phlebotomy center.

Results are reported back to the ordering healthcare provider within 24 hours of receipt of the specimen. A completed, signed laboratory requisition form is needed to initiate the process. If you would like to order IBSchek click here.

Published Clinical Data Validating IBSchek for Diagnosing IBS-D and IBS-M

"Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects" Mark Pimentel, Walter Morales, Ali Rezaie, et al. PLoS One. 2015; 10:e0126438.

"Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome." Rezaie A, Park SC, Morales W et al. Dig Dis Sci. 2017 Jun; 62(6):1480-1485.

"Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico." Schmulson M, Balbuena R, Corona de Law C. Rev Gastroenterol Mex. 2016 Oct - Dec;81(4):236-239.

"The Utility of Measuring Anti-Cytolethal Distending Toxin B and Anti-Vinculin Antibodies in a Tertiary Care Motility Practice: A Free-Range Experience." Pourmorady J, Rezaie A, Pimentel M, et al. Gastroenterology. 2016;4 (Suppl1): S-230.

What is Irritable Bowel Syndrome (IBS)?

Irritable bowel syndrome (IBS) is the most common functional gastrointestinal syndrome in the U.S. It is estimated that up to 45 million people, or 10-15% of the American population, suffer from IBS. About 2 in 3 IBS sufferers are female. IBS affects people of all ages, including children. There are three primary types of IBS. There is IBS with constipation predominance (IBS-C), IBS with diarrhea predominance (IBS-D), and some people have an alternating pattern of constipation and diarrhea, which is called mixed IBS (IBS-M). Some patients don’t fit into these categories easily, and may be referred to as un-subtyped IBS, or IBS-U. Historically, before the development of IBSchek, a proprietary blood test to diagnose IBS, it would take patients approximately 4-6 years to receive a diagnosis of IBS, usually after undergoing a variety of costly and invasive diagnostic procedures. A large-scale study involving more than 2,500 patients confirmed that IBS-D can be a post-infectious condition, where the body demonstrates an autoimmune response to a bacterial toxin resulting from a bout of gastroenteritis (food poisoning). The body responds by producing antibodies to the bacterial toxin (Cdtb) and the body’s host vinculin protein which results in altered intestinal motility.

What are the symptoms of IBS-D?

Patients suffering from IBS-D experience a variety of symptoms, including:

• Diarrhea

• Sudden urges to have bowel movements

• Abdominal pain or discomfort

• Intestinal gas (flatulence)

• Loose stools

• Frequent stools

• Feeling of being unable to completely empty bowels

• Nausea

What are the symptoms of IBS-C?

Patients suffering from IBS-C experience a variety of symptoms, including:

• Chronic or recurrent constipation

• Hard, lumpy stools

• Straining during bowel movements

• Infrequent stools

• Bloating

• Abdominal pain or discomfort

What are the symptoms of IBS-M?

Patients suffering from IBS-M experience a variety of symptoms, including:

• Mixed bowel habits

• Alternating diarrhea and constipation

• Abdominal pain or discomfort